Filing Flows › Standard Biotools (LAB) › Q1 2025
Standard Biotools (LAB) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Standard Biotools (LAB) reported revenue of $40.8M for the first quarter 2025 (Q1 2025), -10% from a year earlier and -13% from the quarter before. Operating margin was -80.8%, net loss $26.0M (63.8% of revenue).
Standard Biotools, Q1 2025: revenue $40.8M (-10% year over year), operating margin -80.8%, net loss $26.0M, operating cash flow −$30.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $40.8M | -13% | -10% |
| Operating profit | −$33.0M | — | — |
| Net earnings | −$26.0M | — | — |
| Operating cash flow | −$30.3M | — | — |
What changed
Revenue was $40.8M in Q1 2025, down 10% year over year and down 13% from the previous quarter.
Gross margin was 48.4%, down 4.7 points from a year earlier. Operating costs exceeded revenue by $33.0M, an operating margin of -80.8%. Operating expenses fell 38% while revenue fell 10%. The quarter ended with a net loss of $26.0M, narrower than the previous quarter's $34.1M loss. Non-operating items added $6.8M, -26% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$30.3M. Non-cash charges added back $3.3M of depreciation and amortization and $9.0M of share-based compensation. Working capital and other items used $16.5M. Capital expenditures of $5.1M exceeded it, leaving free cash flow of −$35.3M.
Questions
What was Standard Biotools' revenue in the first quarter 2025?
Standard Biotools (LAB) reported revenue of $40.8M for the first quarter 2025 (Q1 2025), -10% from a year earlier and -13% from the quarter before.
Was Standard Biotools profitable in the first quarter 2025?
Operating loss was $33.0M (-80.8% of revenue) and net loss $26.0M.
Source: Standard Biotools 10-Q on SEC EDGAR.